中新藥業(600329.SH):津滬深醫藥完成支付天藥集團67%股權收購款
格隆匯3月19日丨中新藥業(600329.SH)公佈,2021年3月19日,公司收到津滬深醫藥出具的《津滬深生物醫藥科技有限公司關於要約收購天津中新藥業集團股份有限公司事宜進展情況的吿知函》。
截至2021年3月19日,津滬深醫藥已根據《產權交易合同》的約定,完成了該次天藥集團67%股權收購事項所涉及的股權轉讓價款的支付。目前,津滬深醫藥、渤海國資及有關各方正在根據《產權交易合同》辦理該次股權轉讓後續相關手續。
該次要約收購股份數量約為2.40億股,佔中新藥業總股本的31.02%;A股要約收購價格為17.43元/股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.